Marisa Conti, DO
Internal Medicine · Millsboro, DENPI 1093717621
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 202 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $700 and has fallen 56.0% since, to $308 in 2025.
Across 202 payments — averaging $16.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$745
- Lilly USA, LLC$482
- GSK$245
- Pfizer$211
- Astellas Pharma US Inc$202
- AstraZeneca$199
- plus $1K from 21 others
What the payments were for
- Food & beverage$3,406100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 42 | $745 |
| Lilly USA, LLC | 32 | $482 |
| GSK | 13 | $245 |
| Pfizer | 12 | $211 |
| Astellas Pharma US Inc | 13 | $202 |
| AstraZeneca | 12 | $199 |
| Johnson & Johnson | 11 | $153 |
| Sanofi Pasteur Inc. | 8 | $139 |
| Merck | 10 | $135 |
| Genentech USA, Inc. | 2 | $122 |
| Kowa Pharmaceuticals America, Inc. | 7 | $121 |
| Amgen | 6 | $96 |
| Boehringer Ingelheim | 5 | $79 |
| Exact Sciences | 5 | $78 |
| AbbVie(2 entities) | 4 | $68 |
| Dexcom, Inc. | 4 | $67 |
| Amarin Pharma, Inc. | 4 | $59 |
| Abbott | 2 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $33 |
| Eisai Inc. | 1 | $23 |
| Novartis | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Medtronic | 1 | $16 |
| Bayer | 1 | $16 |
| Tactile Systems Technology Inc | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$113
How this compares
$3,406 in reported general payments places this provider in the 85th percentile of 477 internal medicine providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 68 | $111,746 |
| TrulicityDulaglutide | 50 | $107,084 |
| OzempicSemaglutide | 57 | $92,465 |
| EliquisApixaban | 37 | $55,781 |
| JanuviaSitagliptin Phosphate | 26 | $38,986 |
| Rosuvastatin Calcium | 483 | $13,618 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $11,249 |
| Atorvastatin Calcium | 325 | $5,537 |
| Levothyroxine Sodium | 459 | $4,785 |
| Duloxetine Hcl | 64 | $4,280 |
| SynthroidLevothyroxine Sodium | 80 | $4,081 |
| Esomeprazole Magnesium | 56 | $3,988 |
| Omeprazole | 201 | $3,649 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $3,322 |
| Metoprolol Succinate | 152 | $3,037 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $79 | $111,74668 claims |
| Lilly USA, LLCTrulicity | $482 | $107,08450 claims |
| Novo NordiskOzempic | $745 | $92,46557 claims |
| PfizerEliquis | $211 | $55,78137 claims |
| MerckJanuvia | $135 | $38,98626 claims |
| GSKBreo Ellipta | $245 | $11,24921 claims |
| AbbVieSynthroid | $68 | $4,08180 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 477 internal medicine providers in Delaware.
Other internal medicine in Millsboro
- Fadi DamouniMillsboro$17K
- Semaan AbboudMillsboro$5K
- Sherin HowettMillsboro$4K
- Seth IvinsNewark$384K
- Beshara HelouGeorgetown$143K
- Tabassum SalamNewark$62K
- Fabricio AlarconGeorgetown$30K
- Jose CastroWilmington$27K
- Marcia Gina CastroWilmington$24K
- Bhaskar PalekarLewes$22K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.